Certifications & Patents


"Global product patent in the United States, Singapore, S. Africa, India recognized innovation that will eventually help 108 diseases and create employment for millions of people"


14.Companies That Infringe Biomix Patents
:
Europian Patent Certificate
:
Entry Barrier via Global Patent Exclusivity
:
Grant Certificate - US
:
Granted Certificate - South Africa
:
Original Certificate - Singapore
:
Patents brief
:
Patent documents
:
Singapore Patent Description
:
Issue Notification US Patent
:
Registration certificate    
 
  Australia
  Singapore
  South Africa
  Kenya
Lab On Chip
:
List of PCT Contracting States - Dec. 2015
:
HDL006 Poter & Clarkson--PCT-IN09-749
:
HDL006 Poter & Clarkson--PCT-IN09-749 (2)
:
Lab on Chip ( PCT International Application )
:
Hospital on Chip (International Publication with ISR)
:
Hospital on Chip (Later publication of amended claims under Article 19)
:
Hospital On Chip Information
:

Regulatory Approvals

Dr.Pawan Saharan, with a vision to provide Health for all, Invented World’s 1st Immunity Drug to prevent and treat AIDS, Swine Flue& other Immunity problems via Broad SpectrumAntiviral - RECEPTOL® that can be an Answer to Covid-19 based on Common Mode of Action after 18 years of R&D globally involving 25,301 human subjects.

Prestigious Who’s Who American Historical Society (Boston) nominated Dr. Saharan as a World Leader in healthcare industry responsible for changing the destiny of nations & human race via the creative contribution in the healthcare sector. Dr. Saharan has global experience in running healthcare industry, including the Pharmaceuticals MNCs and hospitals at the top management level in India & USA.

Dr. Saharan created the first truly Nano-Bio-IT Helix via inventing Globally Patented Colostrum based Nano-Peptides for AIDS therapy : RECEPTOL® that can be used for Covid-19 and all viral infections along with reusable micro-chip diagnostics Lab on Chip and AI based Patented Virtual Specialty Hospital. Late Dr. Abdul Kalam, former President of India, nominated Dr. Saharan for India’s new drug discovery with a funding of INR 120MM (than equal to US$3M)by Dept of Science & technology, Govt. of India.

Canadian and UK Govt. invited Dr. Saharan as the state guest in recognition for his contribution to healthcare and technological alliances via Canada & UK India Business Councils. UK Prime Minister invited Dr. Saharan in March, 2011 as a key note speaker at the UK India Business Council Global Summit on affordable health care in Manchester.

American Association for the Advancement of Science (AAAS), Washington DC nominated Dr.Saharan for the best US Graduate Student Scientist Award for his cover page story on Indian Science in Feb 1984 World’s Top NATURE Journal at youngest age of 21 after he received National Scholarship from GoI at 15.

Dr. Saharan coordinated RECEPTOL® Global Market Research by IPSOS, USA and IRMA, India suggesting 1 out of 3 citizens globally should use the product both as a preventive and treatment for all communicable /immune deficiency disorders in the next 5 years with an estimated market cap of US$ 13 billion. Dr. Saharan via RECEPTOL® is pushing the boundaries of science by accelerating innovation, thus creating a paradigm shift in the Healthcare, Pharma & Wellness industry.

Dr. Saharan’s Hospitals on Chip is an AI based automated, integrated system and platform which helps in managing total health care services including drug discovery and clinical trials in a cost effective and timely manner. This Universal Virtual, Hospital Patented, Health Portal provides services similar to the world’s largest General Hospital in Boston, tele & emergency medicine, CROs, and drug discovery and diagnostics driven by AIKAT (artificial intelligence based knowledge acquisition tools.)

Dr. Saharan’s Lab on Chip is a Mass screening device to detect virus, bacteria, pollutants and biological/ nuclear warfare impact on humans and livestock. The invention is an apparatus which detects the biological state in any given sample using biomarkers and can be perfect tool in current Covid-19 Pandemic scenario.

Published Ref:

https://patents.google.com/patent/US9249188B2/en.

http://medicaltraveltoday.com/spotlight-interview-pawan-saharan-founder-ceo-biomix-network-inc/

https://escientificpublishers.com/receptol-oral-spray-shield-for-coronavirus-proposed-treatment-prevention-as-demonstrated-in-aids-JBI-02-0007



 References for Biological activities
»
Bonavida B Immunomodulatory effect of tumor necrosis factor. Biotherapy 3: 127-33 (1991);
»
Brouckaert P et al Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology 187: 317-29 (1993)
»
Camussi G et al The molecular action of tumor necrosis factor-alpha. European Journal of Biochemistry 202: 3-14 (1991)
»
Cordingley FT et al Tumor necrosis factor as an autocrine tumor growth factor for chronic B cell malignancies. Lancet I: 969-71 (1988)
»
Frater-Schröder M et al Tumor necrosis factor type a, a potent inhibitor of endothelial cell growth in vitro is angiogenic in vivo. Proceedings of the National Academy of Science (USA) 84: 5277-81 (1987)
»
Goillot E et al Tumor necrosis factor as an autocrine growth factor for neuroblastoma. Cancer Research 52: 3194-200 (1992)
»
Grunfeld C and Feingold KR The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3: 143-58 (1991)
»
Larrick JW and Wright SC Cytotoxic mechanism of tumor necrosis factor-alpha FASEB Journal 4: 3215-32 (1990)
»
Larrick JW and Kunchel SL The role of tumor necrosis factor and interleukin in the immuno-inflammatory response. Pharm. Research 5: 129-39 (1988)
»
Last-Barney K et al Synergistic and overlapping activities of tumor necrosis factor-alpha and IL1. Journal of Immunology 141: 527-30 (1988)
»
Merrill JE Effects of Interleukin 1 and tumor necrosis factor alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev. Neurosci. 13: 130-7 (1991)
»
Nacy CA et al Tumor necrosis factor-alpha: Central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 59: 182-4 (1991)
»
Perez C et al A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63: 251-8 (1990)
»
Sato N et al Actions of TNF and IFN-gamma on angiogenesis in vitro. Journal of Investigative Dermatology 95: 85S-9S (1990)
»
Schiller JH et al Tumor necrosis factor, but not other hematopoietic growth factors, prolongs the survival of hairy cell leukemia cells. Leukocyte Research 16:337-46 (1992)
»
Schulze-Osthoff K et al Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF EMBO Journal 12:3095-3104 (1993)
»
Tartaglia LA et al The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proceedings of the National Academy of Science (USA) 88: 9292-6 (1991)
»
Trinchieri G Effects of TNF and lymphotoxin on the hematopoietic system. Immunology Ser. 56: 289-313 (1992)

“Those who dream big only have the capability to achieve big”. We dreamt of making our mother earth free from diseases and in this path we finally innovated Receptol."


Copyright © BIOMIX NETWORK LTD